CMN Weekly (21 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 21, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Helex Bio
Company Type: Therapeutic development
Main focus: Developing gene-editing based therapeutics to treat genetic kidney diseases
Company stage: Pre-clinical
Diseases: Autosomal dominant polycystic kidney disease, inherited retinal dystrophies, and other genetic disorders
Genome-editing tool: CRISPR-Cas9
Funding stage: Private
Location: New York, New York, USA
Website: www.helex.bio
Pipeline: www.helex.bio/technology
Partners:
Helex Bio is a pre-clinical biotechnology company focused on advancing safer invivo gene-editing therapies to treat genetic kidney diseases and other genetic disorders. The company has developed a proprietary lipid nanoparticle delivery system for safe and effective delivery to the kidneys, as well as EPIC-Cure™, a proprietary drug design platform. EPIC-Cure™ seeks to provide a genome-encompassing, data-driven gene-editing drug design for higher precision of editing.
